Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Advances in adeno-associated virus (AAV) -mediated gene therapy are a possibility for commercial production of AAV vectors. Simultaneous efforts are needed to increase the complexity of AAV carrier production techniques and support analysis. In the critical release analysis of clinical gene therapy products, monitoring potentially harmful contaminants is critical to patient safety. A prominent contaminant in many AAV vector preparations is carrier particles lacking genomes, which can significantly increase the dose of AAV capsid proteins and may lead to unintended immune consequences.